Acute myeloid leukemia (AML) can be difficult to treat. Some patients who experience a relapse of their disease or whose AML does not respond to initial therapy are unable to tolerate the side effects of additional chemotherapy. Doctors are therefore seeking new treatments for this disease.
Tigecycline is an antibiotic that has been shown in laboratory studies to kill leukemia cells. In this study, researchers want to identify the highest dose of tigecycline that can be given safely in patients with AML that has persisted or returned despite prior therapy.